{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:42:32Z","timestamp":1790685752275,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001361","name":"Faculty of Science, National University of Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejpb.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:09:47Z","timestamp":1592946587000},"page":"257-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release"],"prefix":"10.1016","volume":"153","author":[{"given":"Shakti","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Braner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshvardhan","family":"Modh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada Xi Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Phillip","family":"Mast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Chichakly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.06.004_b0005","doi-asserted-by":"crossref","unstructured":"H. Havel, G. Finch, P. Strode, M. Wolfgang, S. Zale, I. Bobe, H. Youssoufian, M. Peterson, M.J.T.A.J. Liu, Nanomedicines: From Bench to Bedside and Beyond, AAPS J, 18 (2016) 1373\u20131378.","DOI":"10.1208\/s12248-016-9961-7"},{"key":"10.1016\/j.ejpb.2020.06.004_b0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijpharm.2013.08.079","article-title":"Nanocarriers for intravenous injection\u2013the long hard road to the market","volume":"457","author":"Wacker","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0015","first-page":"6371","article-title":"Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies","volume":"50","author":"Gabizon","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0020","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","article-title":"Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy","volume":"3","author":"Batist","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2020.06.004_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpb.2020.02.001","article-title":"Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model","volume":"149","author":"Jablonka","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0030","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"AAC"},{"key":"10.1016\/j.ejpb.2020.06.004_b0035","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"AAC"},{"key":"10.1016\/j.ejpb.2020.06.004_b0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae - the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.ejpb.2020.06.004_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e13537","article-title":"A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors","volume":"35","author":"Filon","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118733","article-title":"Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: Towards the pharmaceutical development","volume":"572","author":"Maksimenko","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11100489","article-title":"Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced Gadolinium Conjugation Techniques","volume":"11","author":"Feczko","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.06.004_b0065","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.nucmedbio.2009.02.004","article-title":"[(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model","volume":"36","author":"Soundararajan","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ejpb.2020.06.004_b0070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2020.06.004_b0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.103.059535","article-title":"Direct 99mTc Labeling of Pegylated Liposomal Doxorubicin (Doxil) for Pharmacokinetic and Non-Invasive Imaging Studies","volume":"308","author":"Bao","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2020.06.004_b0080","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-018-3643-3","article-title":"Pharmacology, Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil\u00ae or Caelyx\u00ae in advanced ovarian cancer","volume":"82","author":"Bhowmik","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00280-017-3278-9","article-title":"Pharmacology, Comparative plasma and tissue distribution of Sun Pharma\u2019s generic doxorubicin HCl liposome injection versus Caelyx\u00ae (doxorubicin HCl liposome injection) in syngeneic fibrosarcoma-bearing BALB\/c mice and Sprague-Dawley rats","volume":"79","author":"Burade","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00280-004-0825-y","article-title":"Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study","volume":"54","author":"Mross","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00001813-200303000-00008","article-title":"Pharmacokinetics of doxorubicin administered iv as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer","volume":"14","author":"Swenson","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejpb.2020.06.004_b0100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2019.06.029","article-title":"Advanced in silico modeling explains pharmacokinetics and biodistribution of temoporfin nanocrystals in humans","volume":"308","author":"Jablonka","year":"2019","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejpb.2020.06.004_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1008202821328","article-title":"Differential Evolution \u2013 A Simple and Efficient Heuristic for global Optimization over Continuous Spaces","volume":"11","author":"Storn","year":"1997","journal-title":"J. Global Optim."},{"key":"10.1016\/j.ejpb.2020.06.004_b0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1208\/s12248-011-9272-y","article-title":"Dissolution testing for generic drugs: an FDA perspective","volume":"13","author":"Anand","year":"2011","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2020.06.004_b0115","first-page":"987","article-title":"Prolonged Circulation Time and Enhanced Accumulation in Malignant Exudates of Doxorubicin Encapsulated in Polyethylene-glycol Coated Liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0120","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF00685539","article-title":"Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer","volume":"28","author":"Twelves","year":"1991","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13318-017-0430-1","article-title":"Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals","volume":"43","author":"Reijers","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2020.06.004_b0130","first-page":"576","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT: PSP"},{"key":"10.1016\/j.ejpb.2020.06.004_b0135","first-page":"742","article-title":"Progress in Nanomedicine: Approved and Investigational Nanodrugs","volume":"42","author":"Ventola","year":"2017","journal-title":"P&T"},{"key":"10.1016\/j.ejpb.2020.06.004_b0140","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/1097-0142(1955)8:4<796::AID-CNCR2820080425>3.0.CO;2-Y","article-title":"The blood volume in cancer","volume":"8","author":"Berlin","year":"1955","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2020.06.004_b0145","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0150","first-page":"46","article-title":"Red cell and plasma volumes in normal adults","volume":"16","author":"Hurley","year":"1975","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejpb.2020.06.004_b0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/uog.17360","article-title":"Physiological adaptation of maternal plasma volume during pregnancy: a systematic review and meta-analysis","volume":"49","author":"de Haas","year":"2017","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0378-5173(01)00676-7","article-title":"Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles","volume":"221","author":"Panagi","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/187231207780363606","article-title":"Application of Simple Mathematical Expressions to Relate Half-Lives of Drugs in Mice to Those in Humans","volume":"1","author":"Bachmann","year":"2007","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.ejpb.2020.06.004_b0170","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2014.04.018","article-title":"NMR cryoporometry characterisation studies of the relation between drug release profile and pore structural evolution of polymeric nanoparticles","volume":"469","author":"Gopinathan","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acs.molpharmaceut.6b00896","article-title":"Effect of Particle Size on Drug Loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres","volume":"14","author":"Chen","year":"2017","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.06.004_b0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2017.02.006","article-title":"The dispersion releaser technology is an effective method for testing drug release from nanosized drug carriers","volume":"115","author":"Janas","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejpb.2018.11.012","article-title":"Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001","volume":"134","author":"Nothnagel","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.18433\/J3D59T","article-title":"Kinetic analysis of drug release from nanoparticles","volume":"11","author":"Barzegar-Jalali","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.06.004_b0195","unstructured":"P.K. Turner, B. Moser, J. Tuttle, V. Wacheck, Adapting a target-mediated drug disposition (TMDD) model to account for delayed tmax following IV infusion of a monoclonal antibody, in: Annual Meeting of The Population Approach Group in Europe, (2012)."},{"key":"10.1016\/j.ejpb.2020.06.004_b0200","series-title":"Proceedings of the 15th annual conference companion on Genetic and evolutionary computation","first-page":"87","article-title":"Improving uniformity of solution spacing in biobjective differential evolution","author":"Chichakly","year":"2013"},{"key":"10.1016\/j.ejpb.2020.06.004_b0205","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01446807","article-title":"Ueber die numerische Aufl\u00f6sung von Differentialgleichungen","volume":"46","author":"Runge","year":"1895","journal-title":"Mathematische Annalen"},{"key":"10.1016\/j.ejpb.2020.06.004_b0210","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.2042-7158.2011.01429.x","article-title":"Comparison of in-vivo and in-silico methods used for prediction of tissue: plasma partition coefficients in rat","volume":"64","author":"Graham","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0215","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1208\/s12248-016-9969-z","article-title":"A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products","volume":"18","author":"Troiano","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.ejpb.2020.06.004_b0220","doi-asserted-by":"crossref","unstructured":"A. Sm, S.S, Bioequivalence Study of Pegylated Doxorubicin Hydrochloride Liposome (PEGADRIA) and DOXIL\u00ae in Ovarian Cancer Patients: Physicochemical Characterization and Pre-clinical Studies, J. Nanomed. Nanotechnol., 07 (2016).","DOI":"10.4172\/2157-7439.1000361"},{"key":"10.1016\/j.ejpb.2020.06.004_b0225","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0230","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1018907715905","article-title":"Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs","volume":"10","author":"Gabizon","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0235","doi-asserted-by":"crossref","unstructured":"F. Campbell, F.L. Bos, S. Sieber, G. Arias-Alpizar, B.E. Koch, J.R. Huwyler, A. Kros, J. Bussmann, Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake, ACS nano, 12 (2018) 2138\u20132150.","DOI":"10.1021\/acsnano.7b06995"},{"key":"10.1016\/j.ejpb.2020.06.004_b0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1155\/2011\/370308","article-title":"Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers","volume":"2011","author":"Zeng","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ejpb.2020.06.004_b0245","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0014-5793(92)80947-F","article-title":"Gelation of liposome interior. A novel method for drug encapsulation","volume":"312","author":"Lasic","year":"1992","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejpb.2020.06.004_b0250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0005-2736(98)00175-8","article-title":"Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient","volume":"1415","author":"Li","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2020.06.004_b0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2019.08.010","article-title":"A dialysis-based in vitro drug release assay to study dynamics of the drug-protein transfer of temoporfin liposomes","volume":"143","author":"Wallenwein","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0260","article-title":"In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B. Part 2: A clinically relevant approach with PBPK modeling","author":"Diaz de Leon-Ortega","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0265","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1021\/ja02086a003","article-title":"The rate of solution of solid substances in their own solutions","volume":"19","author":"Noyes","year":"1897","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2020.06.004_b0270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.18433\/J3JG61","article-title":"Reciprocal powered time model for release kinetic analysis of ibuprofen solid dispersions in oleaster powder, microcrystalline cellulose and crospovidone","volume":"13","author":"Mohammadi","year":"2010","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.06.004_b0275","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejpb.2018.03.010","article-title":"A comparison of two biorelevant in vitro drug release methods for nanotherapeutics based on advanced physiologically-based pharmacokinetic modelling","volume":"127","author":"Jung","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.06.004_b0280","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1016243313027","article-title":"Comparative Tissue Distribution and Elimination of Amphotericin B Colloidal Dispersion (Amphocil\u00ae) and Fungizone\u00ae After Repeated Dosing in Rats","volume":"12","author":"Wang","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0285","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/AAC.36.2.299","article-title":"Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs","volume":"36","author":"Fielding","year":"1992","journal-title":"AAC"},{"key":"10.1016\/j.ejpb.2020.06.004_b0290","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1158\/1078-0432.CCR-05-1365","article-title":"Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model","volume":"11","author":"Arnold","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejpb.2020.06.004_b0295","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2020.06.004_b0300","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ejpb.2020.06.004_b0305","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0310","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/pharmaceutics11030110","article-title":"Pharmacokinetics and Pharmacodynamics Modeling and Simulation Systems to Support the Development and Regulation of Liposomal Drugs","volume":"11","author":"He","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.06.004_b0315","series-title":"Long Circulating Liposomes: Old Drugs","first-page":"185","article-title":"Am Bisome\u00ae: Long Circulating Liposomal Formulation of Amphotericin B","author":"Adler-Moore","year":"1998"},{"key":"10.1016\/j.ejpb.2020.06.004_b0320","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.107.016188","article-title":"Interspecies prediction of human drug clearance based on scaling data from one or two animal species","volume":"35","author":"Tang","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2020.06.004_b0325","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejpb.2020.06.004_b0330","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ejps.2016.10.036","article-title":"IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results","volume":"96","author":"Margolskee","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.06.004_b0335","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/jphp.12618","article-title":"Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models","volume":"68","author":"Hansmann","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2020.06.004_b0340","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0169-409X(95)00030-B","article-title":"Liposome circulation time and tumor targeting: implications for cancer chemotherapy","volume":"16","author":"Gabizon","year":"1995","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2020.06.004_b0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: Strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Del. Rev."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120301752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120301752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:40:45Z","timestamp":1760546445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120301752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":69,"alternative-id":["S0939641120301752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.06.004","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}